{"product_id":"多替诺雷-dotinurad-ドチヌラド-多替尿苷","title":"Dotinurad Dotinurad Dotinurad 0.5mg Dotinurad 100 tablets for gout and hyperuricemia","description":"\u003cp class=\"MsoNormal\"\u003e \u003cb\u003eDotinurad is a highly selective urate transporter 1 (URAT1) inhibitor developed by Fuji Pharmaceuticals and Eisai of Japan. It is mainly used to treat hyperuricemia and gout, especially for people with renal impaired function or intolerance to traditional drugs.\u003c\/b\u003e\u003c\/p\u003e\n\n\u003cp class=\"MsoNormal\"\u003e \u003cb\u003e1. Basic information of the drug\u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\u003c\/b\u003e \u003c\/p\u003e\n\n\u003col style=\"margin-top: 0cm;\" start=\"1\" type=\"1\"\u003e\n\n\u003cli class=\"MsoNormal\" style=\"mso-list: l0 level1 lfo1; tab-stops: list 36.0pt;\"\u003e\n\n \u003cb\u003eGeneric name\u003c\/b\u003e : Dotinurad; \u003cspan lang=\"EN-US\"\u003eDotinurad\u003c\/span\u003e ; Dotinurad \u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\n\n\u003c\/li\u003e\n\n\u003cli class=\"MsoNormal\" style=\"mso-list: l0 level1 lfo1; tab-stops: list 36.0pt;\"\u003e\n\n \u003cb\u003eProduct name\u003c\/b\u003e : ユリス (Fuji Soup) \u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\n\n\u003c\/li\u003e\n\n\u003cli class=\"MsoNormal\" style=\"mso-list: l0 level1 lfo1; tab-stops: list 36.0pt;\"\u003e\n\n \u003cb\u003eDosage form\u003c\/b\u003e : Oral tablet \u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\n\n\u003c\/li\u003e\n\n\u003cli class=\"MsoNormal\" style=\"mso-list: l0 level1 lfo1; tab-stops: list 36.0pt;\"\u003e\n\n \u003cb\u003eIndications\u003c\/b\u003e : Drug for the treatment of hyperuricemia, drug for inhibiting uric acid transporters, used for gout ( \u003cspan lang=\"EN-US\"\u003eDS: H01532\u003c\/span\u003e ). \u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\n\n\u003c\/li\u003e\n\n\u003cli class=\"MsoNormal\" style=\"mso-list: l0 level1 lfo1; tab-stops: list 36.0pt;\"\u003e\n\n \u003cb\u003eElement\u003c\/b\u003e : \u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\n\n\u003c\/li\u003e\n\n\u003cul style=\"margin-top: 0cm;\" type=\"circle\"\u003e\n\n \u003cli class=\"MsoNormal\" style=\"mso-list: l0 level2 lfo1; tab-stops: list 72.0pt;\"\u003eComposition formula: \u003cspan lang=\"EN-US\"\u003eC\u003c\/span\u003e\u003cspan lang=\"EN-US\" style=\"font-family: 'Cambria Math',serif; mso-bidi-font-family: 'Cambria Math';\"\u003e₁₄\u003c\/span\u003e \u003cspan lang=\"EN-US\"\u003eH\u003c\/span\u003e\u003cspan lang=\"EN-US\" style=\"font-family: 'Cambria Math',serif; mso-bidi-font-family: 'Cambria Math';\"\u003e₉\u003c\/span\u003e \u003cspan lang=\"EN-US\"\u003eCl\u003c\/span\u003e\u003cspan lang=\"EN-US\" style=\"font-family: 'Cambria Math',serif; mso-bidi-font-family: 'Cambria Math';\"\u003e₂\u003c\/span\u003e \u003cspan lang=\"EN-US\"\u003eNO\u003c\/span\u003e\u003cspan lang=\"EN-US\" style=\"font-family: 'Cambria Math',serif; mso-bidi-font-family: 'Cambria Math';\"\u003e₄\u003c\/span\u003e \u003cspan lang=\"EN-US\"\u003eS\u003c\/span\u003e \n\n\u003c\/li\u003e\n\n\u003cli class=\"MsoNormal\" style=\"mso-list: l0 level2 lfo1; tab-stops: list 72.0pt;\"\u003e Molecular weight: \u003cspan lang=\"EN-US\"\u003e358.20\u003c\/span\u003e \n\n\u003c\/li\u003e\n\n\n\u003c\/ul\u003e\n\n\u003cli class=\"MsoNormal\" style=\"mso-list: l0 level1 lfo1; tab-stops: list 36.0pt;\"\u003e\n\n \u003cb\u003eProperties\u003c\/b\u003e : \/\u003c\/li\u003e\n\n\n\u003c\/ol\u003e\n\n\u003cp class=\"MsoNormal\"\u003e \u003cb\u003e2. Usage and Dosage\u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\u003c\/b\u003e\u003c\/p\u003e\n\n \u003cp class=\"MsoNormal\"\u003eAdults: The usual dose is \u003cspan lang=\"EN-US\"\u003e0.5 mg\u003c\/span\u003e per day, after which the dose is gradually increased as needed, while checking the blood uric acid level. The maintenance dose is usually \u003cspan lang=\"EN-US\"\u003e2 mg\u003c\/span\u003e per day, which can be adjusted according to the patient's condition, but the maximum dose should be \u003cspan lang=\"EN-US\"\u003e4 mg\u003c\/span\u003e per day.\u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp class=\"MsoNormal\"\u003e \u003cb\u003e3. Taboo\u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\u003c\/b\u003e\u003c\/p\u003e\n\n\u003cp class=\"MsoNormal\"\u003e It is contraindicated for those who are allergic to the ingredients of this product.\u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp class=\"MsoNormal\"\u003e This medicine is not recommended for patients with hyperuricemia caused by excessive uric acid production.\u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp class=\"MsoNormal\"\u003e Use with caution in pregnant and lactating women.\u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp class=\"MsoNormal\"\u003e \u003cb\u003eIV. Precautions\u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\u003c\/b\u003e\u003c\/p\u003e\n\n\u003cp class=\"MsoNormal\"\u003e Special populations: It can be used by patients with mild to moderate renal impairment; patients with severe renal impairment should use it with caution and adjust the dosage according to the doctor's advice.\u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp class=\"MsoNormal\"\u003e Medication guidance: Maintain adequate drinking water to promote uric acid excretion. It is recommended to monitor blood uric acid levels and renal function indicators.\u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp class=\"MsoNormal\"\u003e Drug storage: Avoid high temperature and humidity, store in a cool and dry place.\u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp class=\"MsoNormal\"\u003e\u003cb\u003e5. Adverse Reactions\u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\u003c\/b\u003e\u003c\/p\u003e\n\n\u003cp class=\"MsoNormal\"\u003e Common (incidence ≥ \u003cspan lang=\"EN-US\"\u003e1%\u003c\/span\u003e ): abnormal liver function (elevated \u003cspan lang=\"EN-US\"\u003eAST\u003c\/span\u003e , \u003cspan lang=\"EN-US\"\u003eALT\u003c\/span\u003e ), nausea, diarrhea\u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp class=\"MsoNormal\"\u003e Uncommon: rash, itching, edema\u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp class=\"MsoNormal\"\u003e Rare: severe liver damage, anaphylactic shock (need to stop the drug and treat urgently).\u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp class=\"MsoNormal\"\u003e \u003cb\u003e6. Drug Interactions\u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\u003c\/b\u003e\u003c\/p\u003e\n\n\u003cp class=\"MsoNormal\"\u003e When used in combination with other uric acid-lowering drugs (such as benzbromarone, febuxostat), changes in uric acid levels should be closely monitored.\u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp class=\"MsoNormal\"\u003e When nephrotoxic drugs (such as \u003cspan lang=\"EN-US\"\u003eNSAIDs\u003c\/span\u003e ) are used simultaneously, renal function should be monitored more closely.\u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp class=\"MsoNormal\"\u003e Combination use with diuretics may reduce the effectiveness of this drug.\u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp class=\"MsoNormal\"\u003e \u003cb\u003e7. Pharmacological Action\u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\u003c\/b\u003e\u003c\/p\u003e\n\n \u003cp class=\"MsoNormal\"\u003e\u003cb\u003eMechanism of action\u003c\/b\u003e : By inhibiting the uric acid transporter \u003cspan lang=\"EN-US\"\u003eSLC22A12\u003c\/span\u003e ( \u003cspan lang=\"EN-US\"\u003eURAT1\u003c\/span\u003e ), it reduces uric acid reabsorption and lowers blood uric acid levels.\u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp class=\"MsoNormal\"\u003e \u003cb\u003e8. Pharmacokinetics\u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\u003c\/b\u003e\u003c\/p\u003e\n\n\u003cp class=\"MsoNormal\"\u003e Absorption: Rapidly absorbed after oral administration, reaching peak value in approximately \u003cspan lang=\"EN-US\"\u003e1\u003c\/span\u003e hour.\u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp class=\"MsoNormal\"\u003e Distribution: High plasma protein binding ( \u003cspan lang=\"EN-US\"\u003e\u0026gt;98%\u003c\/span\u003e )\u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp class=\"MsoNormal\"\u003e Metabolism: Mainly metabolized in the liver\u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp class=\"MsoNormal\"\u003e Excretion: Mainly excreted through bile, partially excreted through kidneys\u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp class=\"MsoNormal\"\u003e Half-life: approximately \u003cspan lang=\"EN-US\"\u003e10\u003c\/span\u003e hours, supporting once-daily dosing.\u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp class=\"MsoNormal\"\u003e \u003cb\u003eIX. Clinical Research\u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\u003c\/b\u003e\u003c\/p\u003e\n\n\u003cp class=\"MsoNormal\"\u003e In a Japanese Phase \u003cspan lang=\"EN-US\"\u003eIII\u003c\/span\u003e clinical trial, \u003cspan lang=\"EN-US\"\u003eDotinurad 1 mg\/\u003c\/span\u003e day treatment for \u003cspan lang=\"EN-US\"\u003e12\u003c\/span\u003e weeks significantly reduced serum uric acid levels and was superior to the placebo group.\u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\n \u003cp class=\"MsoNormal\"\u003eCompared with benzbromarone, it has comparable efficacy in uric acid control but is less hepatotoxic.\u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp class=\"MsoNormal\"\u003e In patients with mild to moderate renal impairment, the efficacy is still good and the drug is well tolerated.\u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp class=\"MsoNormal\"\u003e \u003cb\u003e10. Packaging specifications\u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\u003c\/b\u003e\u003c\/p\u003e\n\n\u003cp class=\"MsoNormal\"\u003e \u003cspan lang=\"EN-US\"\u003e0.5mg 100\u003c\/span\u003e tablets.\u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\n\u003cp class=\"MsoNormal\"\u003e 1mg \u003cspan lang=\"EN-US\"\u003e100\u003c\/span\u003e tablets.\u003c\/p\u003e\n\n\u003cp class=\"MsoNormal\"\u003e 2mg \u003cspan lang=\"EN-US\"\u003e100\u003c\/span\u003e tablets.\u003c\/p\u003e\n\n\u003cp class=\"MsoNormal\"\u003e \u003cb\u003e11. Production Information\u003cspan lang=\"EN-US\"\u003e\u003c\/span\u003e\u003c\/b\u003e\u003c\/p\u003e\n\n\u003cp\u003e \u003cb\u003eManufacturer\u003c\/b\u003e : Fuji Pharmaceutical Co., Ltd.\u003c\/p\u003e","brand":"株式会富士薬品","offers":[{"title":"Default Title","offer_id":49886085054750,"sku":"","price":7000.0,"currency_code":"JPY","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0903\/9957\/2254\/files\/0.5mg.png?v=1750470802","url":"https:\/\/asakusa-yakusoh.com\/en-eng\/products\/%e5%a4%9a%e6%9b%bf%e8%af%ba%e9%9b%b7-dotinurad-%e3%83%89%e3%83%81%e3%83%8c%e3%83%a9%e3%83%89-%e5%a4%9a%e6%9b%bf%e5%b0%bf%e8%8b%b7","provider":"浅草薬粧","version":"1.0","type":"link"}